GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

(RTTNews) - Zymeworks Inc. (ZYME), Wednesday announced that the company has received a cash research milestone payment of $14 million from GSK plc (GSK) associated with a previous milestone.